Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Mobilisering och utfall efter venstängning (MOVE)

17 september 2026 uppdaterad av: Cordis US Corp.

MOVE - Mobilisering och utfall efter venös stängning - Ett prospektivt register över verkliga världens utfall/användning/bevis för MYNX CONTROL™ VENOUS vaskulär stängningsanordning 6F-12F

The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.

Studieöversikt

Detaljerad beskrivning

The study is a single-arm, prospective, multi-center, observational, real-world registry of venous access site closures utilizing MYNX CONTROL™ VENOUS VCD 6F-12F following endovascular procedures. The study will enroll approximately 300 subjects in approximately 15 study sites in the United States.

Studietyp

Observationell

Inskrivning (Faktisk)

339

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90048
        • Cedars Sinai Medical Center
      • Palo Alto, California, Förenta staterna, 94304
        • Stanford University School of Medicine
    • Colorado
      • Littleton, Colorado, Förenta staterna, 80210
        • South Denver Cardiology
    • Florida
      • Orlando, Florida, Förenta staterna, 32803
        • AdventHealth Orlando
    • Illinois
      • Glenview, Illinois, Förenta staterna, 60026
        • Glenbrook Hospital
    • Kansas
      • Overland Park, Kansas, Förenta staterna, 66211
        • KC Heart and Rhythm Institute
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40503
        • Baptist Health Lexington
    • North Carolina
      • Raleigh, North Carolina, Förenta staterna, 27607
        • North Carolina Heart & Vascular Research, LLC
    • Washington
      • Bellevue, Washington, Förenta staterna, 98004
        • Overlake Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study includes patients who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.

Beskrivning

Inclusion Criteria

  1. Able and willing to provide informed consent and to complete a follow-up visit at 14 ± 7 days post-procedure.
  2. Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.
  3. Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
  4. At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events/complications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).

Exclusion Criteria

  1. Presence of bruit, palpable aneurysm, significant candida or groin infection.
  2. Prior to closure, presence of hematoma in the accessed limb.
  3. Currently involved in any other clinical trial that may interfere with the outcomes of this study as determined by the Investigator.
  4. Planned use of other closure devices or techniques other than MYNX CONTROL™ VENOUS VCD 6F-12F.
  5. Life expectancy <12 months.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
MCV VCD Treatment

Subjects who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.

The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs.

MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days.

The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complications
Tidsram: From time of index procedure through end of following day (within 48 hours)

Rate of patients who successfully received a study device at all access sites and had SDD without subsequent hospitalization/intervention for access-site complications either same day post-discharge or the next day

From time of index procedure through end of following day (within 48 hours)
Rate of access-site complications
Tidsram: From time of study device introduction at first access site through 14 days post-procedure

Rate of access-site complications, assessed per standard of care, through 14 days post-procedure, including:

  • Access Site-Related Hematoma > 6 cm documented by ultrasound
  • Local Access Site Infection confirmed by culture and sensitivity, treated with intramuscular or oral antibiotics
  • Allergic Reaction
  • Access site-related bleeding requiring transfusion, surgical intervention, or rehospitalization
  • Pulmonary embolism requiring surgical or endovascular intervention and/or resulting in death, to be confirmed by CT pulmonary angiography, lung ventilation/perfusion scan (VQ scan), or autopsy
  • Ipsilateral deep vein thrombosis, documented by ultrasound
From time of study device introduction at first access site through 14 days post-procedure

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to Ambulation
Tidsram: From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)

Defined as elapsed time (in hours) between removal of the final MCV VCD and when subject stands and walks 20 feet without evidence of rebleeding from any femoral venous access site.

From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
Time to Discharge
Tidsram: From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)

Defined as the elapsed time (in minutes) between removal of the final MCV VCD and when the subject is discharged from the hospital, as recorded on the discharge order.

From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
Time to Hemostasis
Tidsram: From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)

Defined as elapsed time (in minutes) between removal of each MCV VCD and first observed and confirmed venous hemostasis (per access site analysis).

From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
SDD sustained MCV VCD success
Tidsram: From end of index procedure through 14 days post-procedure

Defined as the proportion of subjects who did not require hospital intervention within 14 days post-procedure due to access site-related complications

From end of index procedure through 14 days post-procedure
Device success evaluated at the end of the procedure
Tidsram: End of index procedure

Defined as the ability to deploy the delivery system and deliver the PEG component to achieve hemostasis at each access site

End of index procedure
Procedural Success
Tidsram: From end of index procedure through 14 days post-procedure

Defined as the attainment of final hemostasis at all venous access sites without major venous access site closure-related complications through 14 days

From end of index procedure through 14 days post-procedure
Procedural Time
Tidsram: Index procedure

Defined as time of first sheath insertion until the time of removal of final MCV VCD.

Index procedure
Recovery room time
Tidsram: From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)

Defined as elapsed time (in minutes) between when the subject is transferred to recovery and when the subject is discharged from the hospital, as recorded on the discharge order.

From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
Analysis of Cost Effectiveness - Comprehensive summary of clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes
Tidsram: From start time of index procedure through 14 days post-procedure

An analysis of cost effectiveness will be performed based on a summary of key clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes

From start time of index procedure through 14 days post-procedure
Incidence of urinary catheter usage
Tidsram: From start time of index procedure through end time of index procedure

Number/rate of patients with urinary catheters used during the procedure

From start time of index procedure through end time of index procedure
Incidence of protamine usage
Tidsram: From start time of index procedure through end time of index procedure

Incidence of protamine usage during the procedure

From start time of index procedure through end time of index procedure
Medication Usage
Tidsram: From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)

Rate of patients who are administered anti-platelet, anti-coagulant, anti-thrombotic, local anesthetic, protamine or pain medication

From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

24 november 2025

Primärt slutförande (Faktisk)

26 augusti 2026

Avslutad studie (Faktisk)

26 augusti 2026

Studieregistreringsdatum

Först inskickad

13 november 2025

Först inskickad som uppfyllde QC-kriterierna

21 november 2025

Första postat (Faktisk)

24 november 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera